Open AccessANALYSIS OF ATTRIBUTION OF NOOPEPT TO SUBSTRATES AND MODULATORS OF FUNCTIONAL ACTIVITY OF ABCB1-PROTEIN IN IN VIVO EXPERIMENT
Author(s) -
И. В. Черных,
A. V. Shchulkin,
E. N. Yakusheva,
М В Гацанога,
Н. М. Попова
Publication year - 2017
Publication title -
rossijskij mediko-biologičeskij vestnik imeni akademika i. p. pavlova/rossijskij mediko-biologičeskij vestnik imeni akademika i.p. pavlova
Language(s) - English
Resource type - Journals
eISSN - 2500-2546
pISSN - 0204-3475
DOI - 10.23888/pavlovj2017130-41
Subject(s) - pharmacokinetics , fexofenadine , verapamil , pharmacology , in vivo , chemistry , g protein , high performance liquid chromatography , chromatography , medicine , biology , biochemistry , receptor , calcium , microbiology and biotechnology , organic chemistry
In the article the influence of nootropic drug Noopept (N-phenyl-acetyl-L-prolylglycine ethyl ester) on the functional activity of ABCB1-protein is analyzed and attribution of this drug to the transport protein substrates is studied on male Chinchilla rabbits. Functioning of the transport protein was estimated by the pharmacokinetics of its marker substrate - fexofenadine. Fexofenadine was introduced intragastrically one time in the dose 67,5 mg/kg b.w. before and after 14-day introduction of Noopept in the dose 10 mg/kg b.w. 3 times a day. The quantity of the substance was determined by HPLC method according to the previously developed procedure.Belonging of Noopept to ABCB1-protein substrates was estimated by comparison of its pharmacokinetic parameters before and after a course of introduction of verapamil (the known inhibitor of the ABCB1-protein) into male rabbits in the dose 20 mg/kg b.w. 3 times a day. The pharmacokinetics of Noopept was studied by the original HPLC method.It was found that the course of Noopept introduction did not lead to any reliable changes in the pharmacokinetic parameters of the ABCB1-protein marker substrate - fexofenadine, which may evidence preservation of the functional activity of the given transport protein at the initial level. It was also found that the pharmacokinetics of Noopept remained unchanged after a course of introduction of ABCB1-protein inhibitor - verapamil - in to the male rabbits, that is, Noopept is not a substrate of the given transport protein.